tert-butyl N-[(1S)-1-(methylcarbamoyl)-3-phenylpropyl]carbamate | 110755-67-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl N-[(1S)-1-(methylcarbamoyl)-3-phenylpropyl]carbamate
• 英文别名: N-BOC-L-homophenylalanine-N-methylamide；tert-butyl N-[(2S)-1-(methylamino)-1-oxo-4-phenylbutan-2-yl]carbamate
• CAS: 110755-67-4
• 化学式: C₁₆H₂₄N₂O₃
• 分子量: 292.378
• InChiKey: JVCLZXHUDNXRTM-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[(1S)-1-(methylcarbamoyl)-3-phenylpropyl]carbamate 在 三氟乙酸 作用下， 反应 0.5h， 生成 (S)-2-amino-N-methyl-4-phenylbutanamide
  参考文献：
  名称：

  Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors

  摘要：

  The synthesis and biological evaluation of orally active inhibitors of matrix metalloproteinase are reported. Modifications of the P2' position and the a-substituent of hydroxamic acid derivatives were carried out, and revealed that the P2' substituent influenced the MMP inhibitory activities in vitro and in plasma after oral administration. The hydroxamates with phenylglycine at the P2' position were absorbed well orally. Compound 15e, which exhibited the longest duration of inhibitory activity in plasma after oral administration among the phenylglycine derivatives (5a-5d, 15a, 15c, 15e), was evaluated in a rat adjuvant arthritis model. A reduction in hind foot pad swelling and improvements of some inflammatory parameters were demonstrated when the compound was administered orally. These results indicate the potential of MMP inhibitors for rheumatoid arthritis. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00028-x
• 作为产物：
  描述：

  Boc-L-高苯丙氨酸 、 甲胺 在 氯甲酸乙酯 、 三乙胺 作用下， 生成 tert-butyl N-[(1S)-1-(methylcarbamoyl)-3-phenylpropyl]carbamate
  参考文献：
  名称：

  Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors

  摘要：

  The synthesis and biological evaluation of orally active inhibitors of matrix metalloproteinase are reported. Modifications of the P2' position and the a-substituent of hydroxamic acid derivatives were carried out, and revealed that the P2' substituent influenced the MMP inhibitory activities in vitro and in plasma after oral administration. The hydroxamates with phenylglycine at the P2' position were absorbed well orally. Compound 15e, which exhibited the longest duration of inhibitory activity in plasma after oral administration among the phenylglycine derivatives (5a-5d, 15a, 15c, 15e), was evaluated in a rat adjuvant arthritis model. A reduction in hind foot pad swelling and improvements of some inflammatory parameters were demonstrated when the compound was administered orally. These results indicate the potential of MMP inhibitors for rheumatoid arthritis. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00028-x

文献信息

• Hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity
  申请人：——

  公开号：US20030114529A1

  公开（公告）日：2003-06-19

  The present invention concerns the generation of hydroxamic acid thrombospondin-peptide analogs that inhibit aggrecanase activity. These analogs are useful in the treatment of diseases characterized by cartilage degradation, such as osteoarthritis, rheumatoid arthritis spondylarthropathies, and septic arthritis. The invention describes a novel small molecule, enzyme inhibitor that binds both the enzyme and its naturally occurring substrate.

  本发明涉及生成羟肟酸血栓素肽类似物，其抑制聚集素酶活性。这些类似物在治疗以软骨降解为特征的疾病中有用，例如骨关节炎、类风湿性关节炎、脊柱关节病和化脓性关节炎。本发明描述了一种新型的小分子酶抑制剂，它能同时结合酶和其天然底物。
• Novel urea derivatives
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：US20020198376A1

  公开（公告）日：2002-12-26

  Objects of the present invention are to create compounds having urea structure as basic structure and having a sulfur atom and an amide bond in side chains and to find pharmacological effects thereof, particularly TNF-&agr; production inhibitory effects. The present invention provides compounds represented by the following formula [I] wherein R 1 is H, alkyl, aromatic, R A —CO—, R C —S— or the formula [II]; R 2 , R 3 and R 4 are H, alkyl, alkenyl, cycloalkyl, cycloalkenyl or aromatic; R 5 and R 6 are H, alkyl, alkenyl, cycloalkyl, cycloalkenyl or aromatic; R 5 and R 6 can together form a nonaromatic heterocyclic ring; R7 is H, alkyl, cycloalkyl, hydroxy, mercapto, phenyl, R B —O—, R C —S—, R D —COS—, R E —OCO—, R F —N(R G )— or —CONHOH; and A 1 and A 2 are alkylene. 1

  本发明的目的是创建具有尿素结构作为基本结构并在侧链中具有硫原子和酰胺键的化合物，并发现其药理作用，特别是TNF-α生产抑制作用。本发明提供由以下式子（I）表示的化合物，其中R1为H、烷基、芳香基、RA—CO—、RC—S—或式子（II）；R2、R3和R4为H、烷基、烯基、环烷基、环烯基或芳香基；R5和R6为H、烷基、烯基、环烷基、环烯基或芳香基；R5和R6可以一起形成非芳香杂环；R7为H、烷基、环烷基、羟基、巯基、苯基、RB—O—、RC—S—、RD—COS—、RE—OCO—、RF—N(RG)—或—CONHOH；A1和A2为烷基。
• NOVEL UREA DERIVATIVES
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1072591A1

  公开（公告）日：2001-01-31

  Objects of the present invention are to create compounds having urea structure as basic structure and having a sulfur atom and an amide bond in side chains and to find pharmacological effects thereof, particularly TNF-α production inhibitory effects. The present invention provides compounds represented by the following formula [I] wherein R1 is H, alkyl, aromatic, RA-CO-, RC-S- or the formula [II]; R2, R3 and R4 are H, alkyl, alkenyl, cycloalkyl, cycloalkenyl or aromatic; R5 and R6 are H, alkyl, alkenyl, cycloalkyl, cycloalkenyl or aromatic; R5 and R6 can together form a nonaromatic heterocyclic ring; R7 is H, alkyl, cycloalkyl, hydroxy, mercapto, phenyl, RB-O-, RC-S-, RD-COS-, RE-OCO-, RF-N(RG)- or ―CONHOH; and A1 and A2 are alkylene.

  本发明的目的是创造出以脲结构为基本结构、侧链中具有一个硫原子和一个酰胺键的化合物，并发现其药理作用，特别是抑制TNF-α产生的作用。 本发明提供了由下式[I]代表的化合物 其中 R1 是 H、烷基、芳香族、RA-CO-、RC-S- 或式[II]；R2、R3 和 R4 是 H、烷基、烯基、环烷基、环烯基或芳香族；R5 和 R6 是 H、烷基、烯基、环烷基、环烯基或芳香族；R5 和 R6 可共同形成一个非芳香族杂环；R7 是 H、烷基、环烷基、羟基、巯基、苯基、RB-O-、RC-S-、RD-COS-、RE-OCO-、RF-N(RG)- 或 -CONHOH；以及 A1 和 A2 是亚烷基。
• Discovery and Structural Characterization of Small Molecule Binders of the Human CTLH E3 Ligase Subunit GID4
  作者：Chetan K. Chana、Pierre Maisonneuve、Ganna Posternak、Nicolas G.A. Grinberg、Juline Poirson、Samara M. Ona、Derek F. Ceccarelli、Pavel Mader、Daniel J. St-Cyr、Victor Pau、Igor Kurinov、Xiaojing Tang、Dongjing Deng、Weiren Cui、Wenji Su、Letian Kuai、Richard Soll、Mike Tyers、Hannes L. Röst、Robert A. Batey、Mikko Taipale、Anne-Claude Gingras、Frank Sicheri

  DOI：10.1021/acs.jmedchem.2c00509

  日期：2022.10.13
• A HYDROXAMIC ACID THROMBOSPONDIN PEPTIDE ANALOG THAT INHIBITS AGGRECANASE ACTIVITY
  申请人：MP Biomedicals, L.L.C.

  公开号：EP1480946A2

  公开（公告）日：2004-12-01